K. Wells-Knecht

发表

Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose.

J. Baynes, S. Thorpe, K. Wells-Knecht, 1995, Biochemistry.

New biomarkers of Maillard reaction damage to proteins.

J. Baynes, S. Thorpe, M. Wells-Knecht, 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins.

J. Baynes, S. Thorpe, K. Wells-Knecht, 1995, Biochemistry.

Glycation, Glycoxidation, and Cross-Linking of Collagen by Glucose: Kinetics, Mechanisms, and Inhibition of Late Stages of the Maillard Reaction

J. Baynes, S. Thorpe, K. Wells-Knecht, 1994, Diabetes.

3-Deoxyfructose Concentrations are Increased in Human Plasma and Urine in Diabetes

T. Lyons, J. Baynes, S. Thorpe, 1994, Diabetes.

METABOLIC ACTIVATION OF PIOGLITAZONE IDENTIFIED FROM RAT AND HUMAN LIVER MICROSOMES AND FRESHLY ISOLATED HEPATOCYTES

M. Wells-Knecht, K. Wells-Knecht, Z. Zhao, 2005, Drug Metabolism and Disposition.

Characterization of an Imidazolium Salt Formed from Glyoxal and N.alpha.-Hippuryllysine: A Model for Maillard Reaction Crosslinks in Proteins

J. Baynes, K. Wells-Knecht, E. Brinkmann, 1995 .

Characterization of an imidazolium compound formed by reaction of methylglyoxal and N-hippuryllysine

J. Baynes, S. Thorpe, K. Wells-Knecht, 1995 .

Aminoguanidine and the effects of modified LDL on cultured retinal capillary cells.

A. Jenkins, T. Lyons, W. Li, 2000, Investigative ophthalmology & visual science.

Discovery of Clinical Candidate CEP-37440, a Selective Inhibitor of Focal Adhesion Kinase (FAK) and Anaplastic Lymphoma Kinase (ALK).

A. Ghose, P. Dobrzanski, E. Bruckheimer, 2016, Journal of medicinal chemistry.

A structural screening approach to ketoamide-based inhibitors of cathepsin K.

K. Wells-Knecht, Aaron B. Miller, D. N. Deaton, 2005, Bioorganic & medicinal chemistry letters.

L-Arginine inhibits in vitro nonenzymatic glycation and advanced glycosylated end product formation of human serum albumin

D. Bryant, K. Wells-Knecht, P. Wiesenfeld, 1996, Amino Acids.

Design of small molecule ketoamide-based inhibitors of cathepsin K.

K. Wells-Knecht, D. N. Deaton, L. Wright, 2004, Bioorganic & medicinal chemistry letters.

Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase.

A. Ghose, B. Ruggeri, K. Wells-Knecht, 2012, Journal of medicinal chemistry.

Design, synthesis, and anaplastic lymphoma kinase (ALK) inhibitory activity for a novel series of 2,4,8,22-tetraazatetracyclo[14.3.1.1³,⁷.1⁹,¹³]docosa-1(20),3(22),4,6,9(21),10,12,16,18-nonaene macrocycles.

A. Ghose, K. Wells-Knecht, H. Breslin, 2012, Journal of medicinal chemistry.

A selective, orally bioavailable 1,2,4-triazolo[1,5-a]pyridine-based inhibitor of Janus kinase 2 for use in anticancer therapy: discovery of CEP-33779.

Jennifer L. Mason, Pawel Dobrzanski, Bruce D. Dorsey, 2012, Journal of medicinal chemistry.

Novel, potent P2-P3 pyrrolidine derivatives of ketoamide-based cathepsin K inhibitors.

J. A. Ray, L. Shewchuk, A. Hassell, 2006, Bioorganic & medicinal chemistry letters.

Compositional differences between Copaxone and Glatopa are reflected in altered immunomodulation ex vivo in a mouse model

Kevin Fowler, D. Laifenfeld, S. Kolitz, 2017, Annals of the New York Academy of Sciences.

Strategies to mitigate the bioactivation of 2-anilino-7-aryl-pyrrolo[2,1-f][1,2,4]triazines: identification of orally bioavailable, efficacious ALK inhibitors.

K. Wells-Knecht, H. Breslin, B. Dorsey, 2012, Journal of medicinal chemistry.

Cassette dosing: rapid in vivo assessment of pharmacokinetics

P. Woollard, K. Wells-Knecht, K. Adkison, 1998 .

Elements of diabetic nephropathy in a patient with GLUT 2 deficiency.

B. Szwergold, J. Baynes, R. Santer, 2005, Molecular genetics and metabolism.

Semicarbazone-based inhibitors of cathepsin K, are they prodrugs for aldehyde inhibitors?

L. Shewchuk, A. Hassell, R. Gampe, 2006, Bioorganic & medicinal chemistry letters.

2-Cyano-4-fluoro-1-thiovalylpyrrolidine analogues as potent inhibitors of DPP-IV.

T. Tomaszek, K. Wells-Knecht, J. Lenhard, 2005, Bioorganic & medicinal chemistry letters.

Physicochemical and Biological Characterization of both Copaxone and the European Follow-On Glatiramer Acetate Product (P1.400)

M. Hayden, B. Timan, R. Laufer, 2018 .

Orally bioavailable small molecule ketoamide-based inhibitors of cathepsin K.

K. Wells-Knecht, F. Tavares, D. N. Deaton, 2004, Bioorganic & medicinal chemistry letters.

2,7-Pyrrolo[2,1-f][1,2,4]triazines as JAK2 inhibitors: modification of target structure to minimize reactive metabolite formation.

Jennifer L. Mason, K. L. Milkiewicz, K. Wells-Knecht, 2011, Bioorganic & Medicinal Chemistry Letters.

Modification of CellSensor irf1-bla TF-1 and irf1-bla HEL assays for direct comparison of wild-type JAK2 and JAK2 V617F inhibition.

Jennifer L. Mason, K. Wells-Knecht, T. Angeles, 2011, Assay and drug development technologies.

2,7-Disubstituted-pyrrolotriazine kinase inhibitors with an unusually high degree of reactive metabolite formation.

M. Yazdanian, K. Wells-Knecht, D. Gingrich, 2011, Chemical research in toxicology.

Pathways of the Maillard Reaction In Vitro and In Vivo

J. Baynes, S. Thorpe, M. Wells-Knecht, 2005 .

Metabolism of fructose-3-phosphate in the diabetic rat lens.

T. Brown, B. Szwergold, A. Taylor, 1995, Archives of biochemistry and biophysics.

P2-P3 conformationally constrained ketoamide-based inhibitors of cathepsin K.

J. A. Ray, L. Shewchuk, A. Hassell, 2005, Bioorganic & medicinal chemistry letters.

Design of potent, selective, and orally bioavailable inhibitors of cysteine protease cathepsin k.

L. Shewchuk, A. Hassell, K. Wells-Knecht, 2004, Journal of medicinal chemistry.

A. Ghose, K. Wells-Knecht, H. Breslin, 2012, Journal of medicinal chemistry.